Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3616 for Dedifferentiated Liposarcoma (Phase II)
CTR20221343Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of culmerciclib in dedifferentiated liposarcoma (DDL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started May 2022; status: terminated.
02
Drugs
culmerciclib
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on CTR20221343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221343.